{"filing":{"accession_number":"0001690585-26-000033","cik":"0001690585","ticker":"DNTH","company_name":"Dianthus Therapeutics, Inc. /DE/","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-04","primary_document":"dnth-20260804.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1690585/000169058526000033/dnth-20260804.htm"},"events":[{"id":24261,"run_id":21968,"accession_number":"0001690585-26-000033","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed on August 4, 2026. The press release discloses quarterly financial results including R\u0026D expenses of $48.7 million, G\u0026A expenses of $13.6 million, and a net loss of $50.2 million ($0.90 per share), along with cash position of approximately $1.2 billion. The filing explicitly states \"Dianthus Therapeutics, Inc. (the \"Company\") issued a press release announcing the Company's financial results for the quarter ended June 30, 2026\" and the press release is furnished as Exhibit 99.1, which is the standard format for earnings releases under Item 2.02.","company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24753,"accession_number":"0001690585-26-000033","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed on August 4, 2026. The press release discloses quarterly financial results including R\u0026D expenses of $48.7 million, G\u0026A expenses of $13.6 million, and a net loss of $50.2 million ($0.90 per share), along with cash position of approximately $1.2 billion. The filing explicitly states \"Dianthus Therapeutics, Inc. (the \"Company\") issued a press release announcing the Company's financial results for the quarter ended June 30, 2026\" and the press release is furnished as Exhibit 99.1, which is the standard format for earnings releases under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:16:51.807972+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24753,"accession_number":"0001690585-26-000033","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed on August 4, 2026. The press release discloses quarterly financial results including R\u0026D expenses of $48.7 million, G\u0026A expenses of $13.6 million, and a net loss of $50.2 million ($0.90 per share), along with cash position of approximately $1.2 billion. The filing explicitly states \"Dianthus Therapeutics, Inc. (the \"Company\") issued a press release announcing the Company's financial results for the quarter ended June 30, 2026\" and the press release is furnished as Exhibit 99.1, which is the standard format for earnings releases under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:16:51.807972+00:00","company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","filing_date":"2026-08-04"}]}